Methods and compositions for treatment of disorders and diseases involving RDH12

US11197936B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-11197936-B2
Application numberUS-201716314179-A
CountryUS
Kind codeB2
Filing dateJul 7, 2017
Priority dateJul 8, 2016
Publication dateDec 14, 2021
Grant dateDec 14, 2021

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

Codon optimized nucleic acid sequences for RDH12 are provided, as well as recombinant viral vectors, such as AAV, expression cassettes, proviral plasmids or other plasmids containing the codon optimized sequence for functional RDH12. Recombinant vectors are provided that express the codon optimized, functional RDH12. Compositions containing these codon optimized sequences are useful in methods for treating, retarding or halting certain blinding diseases resulting from the absence, deficiency or inappropriate expression of RDH12. Other compositions and methods are providing for correcting a non-functional, defective or inadequately expressed native RDH12.

First claim

Opening claim text (preview).

The invention claimed is: 1. A nucleic acid comprising a nucleotide sequence of SEQ ID NO: 5 encoding human RDH12. 2. An expression cassette comprising a nucleotide sequence of SEQ ID NO: 5 encoding human RDH12. 3. The expression cassette of claim 2 , wherein said nucleotide sequence is operatively associated with expression control sequences that can direct expression of the nucleotide sequence in a host cell. 4. The expression cassette of claim 2 , which is a recombinant adeno-associated virus (AAV) expression cassette further comprising a 5′ AAV inverted terminal repeat (ITR) and a 3′ AAV ITR, and expression control sequences that can direct expression of the nucleotide sequence in a host cell. 5. The rAAV expression cassette of claim 4 , wherein the expression control sequences comprise a rhodopsin kinase promoter. 6. A vector or plasmid comprising the expression cassette of claim 2 . 7. A vector or plasmid comprising the expression cassette of claim 4 . 8. A recombinant adeno-associated virus (AAV) comprising an AAV capsid protein and a nucleotide sequence comprising a sequence set forth in SEQ ID NO: 5 encoding human RDH12 under the control of regulatory sequences which can express the human RDH12 in the photoreceptor cells of a subject. 9. The rAAV according to claim 8 , wherein the rAAV comprises an AAV8 capsid, or variant thereof, an AAV7 capsid, or variant thereof, an AAV5 capsid, or variant thereof, or an AAV2 capsid, or variant thereof. 10. The rAAV according to claim 8 , wherein the rAAV is a self-complementary AAV. 11. A host cell comprising the expression cassette of claim 2 . 12. A composition comprising a nucleic acid molecule comprising a nucleotide sequence set forth in SEQ ID NO: 5 encoding human RDH12 under the control of regulatory sequences which can direct expression thereof in ocular cells; and a carrier or excipient suitable for delivery to the ocular cells of a subject. 13. The composition of claim 12 , further comprising a recombinant virus comprising an AAV capsid protein and said nucleotide sequence. 14. The nucleic acid of claim 1 , wherein the nucleotide sequence comprises nucleotides 1 to 949 of SEQ ID NO: 5. 15. The expression cassette according to claim 2 , wherein the nucleotide sequence comprises nucleotides 1 to 949 of SEQ ID NO: 5. 16. The rAAV according to claim 8 , wherein the nucleotide sequence comprises nucleotides 1 to 949 of SEQ ID NO: 5. 17. A rAAV comprising an AAV8 capsid and an expression cassette comprising: a) a 5′ AAV ITR; b) a rhodopsin kinase promoter; c) the nucleotide sequence set forth in SEQ ID NO: 5; and d) a 3′ AAV ITR.

Assignees

Inventors

Classifications

  • A61K48/00Primary

    Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy · CPC title

  • involving nucleic acids · CPC title

  • Vectors comprising a coding region that has been codon optimised for expression in a respective host · CPC title

  • viral genome or elements thereof as genetic vector · CPC title

  • General methods for enhancing the expression · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US11197936B2 cover?
Codon optimized nucleic acid sequences for RDH12 are provided, as well as recombinant viral vectors, such as AAV, expression cassettes, proviral plasmids or other plasmids containing the codon optimized sequence for functional RDH12. Recombinant vectors are provided that express the codon optimized, functional RDH12. Compositions containing these codon optimized sequences are useful in methods …
Who is the assignee on this patent?
Univ Pennsylvania
What technology area does this patent fall under?
Primary CPC classification A61K48/00. Mapped technology areas include Human Necessities.
When was this patent published?
Publication date Tue Dec 14 2021 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 2 related publications on this page (citations in our corpus or others sharing the same primary CPC).